+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuropathic Pain"

Chemotherapy Induced Pain Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Chemotherapy Induced Pain Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Inflammatory Pain Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Inflammatory Pain Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Neuropathic Back Pain Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Neuropathic Back Pain Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 100 Pages
  • Global
From
Post Surgical Pain Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Post Surgical Pain Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Chronic Neuropathic Pain Pipeline Analysis Report 2025 - Product Thumbnail Image

Chronic Neuropathic Pain Pipeline Analysis Report 2025

  • Report
  • March 2026
  • 200 Pages
  • Global
From
Gabapentin Market Report and Forecast 2025-2034 - Product Thumbnail Image

Gabapentin Market Report and Forecast 2025-2034

  • Report
  • July 2025
  • 350 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation. The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy. Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more